Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thrush Clear all

Conditions: Candidemia
Interventions: Interferon Gamma-1B; Drug
Lead sponsor: Radboud University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Candidemia
Interventions: Micafungin, Caspofungin; Drug
Lead sponsor: Gary E. Stein, Pharm.D.; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Bacterial Vaginosis, Vulvovaginal Candidiasis, Trichomoniasis
Interventions: NAAT testing; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fever, Mycoses, Neutropenia
Interventions: FK463; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions: Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bacteremia, Candidemia
Interventions: RaPID/BSI Test; Diagnostic Test
Lead sponsor: HelixBind, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candidiasis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Vaginitis
Interventions: Terazol or oral fluconazole for candidal vaginitis, Metronidazole or Clindamycin for Bacterial Vaginosis, Flagyl for definitively diagnosed vaginal trichomoniasis, Empiric Management; Drug · Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Invasive Candidiasis
Interventions: Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Interventions: Ruxolitinib; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions: Veronate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Days to 5 Days
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more

Conditions: Candidemia, Candidiasis, Invasive
Interventions: Fosmanogepix, Caspofungin, Fluconazole, Placebo; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more

Conditions: Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB); Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Fungal Infection, Candidiasis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Candidiasis
Interventions: fluconazole, placebo; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 2 Days to 5 Days
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 33
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candidiasis, Oral, HIV Infections
Interventions: L-743,872; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rahway, New Jersey

Conditions: Candidemia
Interventions: Anidulafungin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 7 more

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Ketoconazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more

Conditions: Infection, Candida, Candidiasis, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 3 Days to 120 Days
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 20
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 16 more

Conditions: Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Search by objective public record fields.

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women

The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Early Diagnosis of Candidiasis in Premature Infants

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp